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Abstract 
Articular chondrocytes derived from osteoarthritic tissues (OA-HAC) show a severely 
reduced chondrogenic commitment. This impairment undermines their use for tissue-
engineered cartilage repair, which relies on cell proliferation and growth to meet the 
therapeutic needs but also on efficient cell plasticity to recover the chondrogenic 
phenotype. Reversine (Rev), a 2,6-disubstituted purine inhibitor of spindle-assembly 
checkpoints, was described to convert differentiated mesenchymal cells to their 
undifferentiated precursors. We hypothesized that Rev exposure could divert OA-HAC to 
more plastic cells, re-boosting their subsequent commitment. HAC were enzymatically 
released from osteoarthritic cartilage specimens, expanded for two weeks and treated with 
5 µM Rev in DMSO or with DMSO alone for 6 days. Cell growth was assessed by the 
AlamarBlueTM assay. Cytoskeletal structure, endoproliferation and caspase-3-
immunopositivity were assayed by epifluorescence microscopy. The OA-HAC chondrogenic 
performance was evaluated by quantitative RT-PCR for GAPDH, Sox9, Aggrecan (Agg), type-II 
collagen (Col2), Ki67, CyclinD1, TGFβ-1, -2 and -3, Interleukin 1-β and -6 (IL-1β, IL-6); SMAD 3 
and 7, and VEGF. Rev-treated OA-HAC recovered polygonal morphology and reduced Ki67 
expression and proliferation. Cell-cycle impairment accounted for altered cytoskeletal 
organization, endoproliferation and apoptosis, while a compensatory mechanism sustained 
the increased CyclinD1 transcript levels. Sox9, Agg and TGFs were overexpressed, but not 
Col2. Interleukins transcripts were massively down-regulated. These events were dose-
related and transient. Overall, in spite of a higher Rev-induced transcriptional activity for 
ECM components and in spite of a Rev-treated cell phenotype closer to that of the 3D-
native articular chondrocyte, Reversine effects seem unleashed from a full regained 
chondrogenic potential.  
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1. INTRODUCTION 
Cell-based therapies have been suggested for clinical treatments of joint cartilage in 
degenerative diseases. However, in the context of osteoarthritis (OA), cartilage tissue 
engineering has not held the premises and it has not yet become a breakthrough in therapy. 
Indeed differentiated chondrocytes show stem cell markers, indicating the transit-
amplifying nature of these cells (Tiku and Sabaawy, 2015). It has also been  reported that 
more progenitors resided in the OA synovial fluid (Jones et al., 2008) and that OA cartilage 
contains more CD105+ and CD166+ cells than healthy tissue, possibly as a direct response to 
cartilage damage or by migration from the synovia and/or subchondral bone marrow 
(Alsalameh et al., 2004). In spite of the availability of potential repair cells, however, tissue 
regrowth is generally not observed within OA pathological environments, particularly if 
vertical fissures require lateral integration of the neo-generated tissue (Brandt et al., 2008). 
Progenitor cells extracted from patients with joint degenerative cartilage defects have in 
fact always exhibited a markedly lower chondrogenic potential in vitro, either if derived 
from the synovia (Krawetz et al., 2012), from the bone marrow (Murphy et al., 2002) or 
from the cartilage itself (Dorotka et al., 2005).  In addition, the alterations in the levels of 
cytokines, chemokines and growth factors, due to the disrupted tissue homeostasis, are 
clear sources of concern (Jayasuriya et al., 2014). In spite of the attempts performed to 
exploit cell therapy for regenerative purposes, to refine the re-implantation techniques, to 
up-grade specific culture conditions and to use advanced biomaterials to meet the request 
of orthopedic surgeons (Mardones et al., 2015), the bottom line of a large body of past and 
current literature is that OA chondrocytes are not at all suitable chondroprogenitors to be 
re-addressed toward proliferation and differentiation to replace the lost tissue. A 
strengthening of their differentiation and re-differentiation potential is therefore crucial, if 
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those cells are envisaged for cartilage repair, being OA patients the largest clinical target for 
cartilage resurfacing. In this light, we took into consideration the early work of Chen and 
coll., which screened combinatorial libraries of small molecules to identify target 
compounds that can induce the de-differentiative process (Chen et al., 2006). The potential 
of reversine was confirmed  in  myoblasts dedifferentiation (Chen et al., 2007) or in dermal 
fibroblasts (Chen et al., 2004); its action was exploited to induce cell differentiation toward 
the neuroectodermal lineage (Lee et al., 2009) while its growth inhibition effect was 
confirmed in cancer cell lines (Bijian et al., 2013). Although somatic cells are thought to be 
stably committed to their terminal fate, emerging evidences have indicated that de-
differentiation may occur upon nuclear transfer (Wilmut et al., 1997), cell fusion (Ying et al., 
2002) or genetic reprogramming (Karagiannis and Yamanaka, 2014). Reversine, instead, a 
2,6 di-substitued purine, seems to chemically reprogram cells to a different plasticity level, 
an ability that provides an attractive clinical appeal. The mechanism of action is thought to 
interfere with the activity of Aurora kinase B (Amabile et al., 2009). The members of the 
Aurora S/T kinase family are involved in the stabilization of the microtubule attachment at 
the kinetochore location of each chromosome, since their phosphorylating activity on target 
proteins decrease microtubule-binding affinity at the centromers (Santaguida et al., 2010). 
These proteins, then, contribute to the great deal of accuracy of the mitotic process. Thus 
the use of small molecules that increase mammalian cell plasticity could provide benefits to 
generate different types of progenitors for therapeutic applications, as already tested  to  
maximize cardiomyocyte development from progenitor cells (Pikir et al., 2012). Moreover 
reversine was also shown to support the expression of a de-differentiated phenotype in cells 
of the annulus fibrosus, potentiating the chondrogenic differentiation of the treated cells, 
although derived from normal tissue (Saraiya et al., 2010). Based on these findings we 
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evaluated if reversine treatment could be applied to ex-vivo cultured human OA articular 
chondrocytes to reprogram these lineage-committed cells and to obtain more performing 
chondrocytes. This would, in turn, amplify the therapeutic indications of cell-based cartilage 
resurfacing, particularly reducing the initial limitations relative to donor tissue health 
conditions. 
 
2. MATERIALS AND METHODS 
2.1 Cell cultures 
Human articular chondrocytes (HAC) were isolated from biopsies derived from three 
different male donors (age range: 68-83 years) undergoing total knee arthroplasty.  Patients 
had signed an informed consent approved by the Ethical Committee of the IRCCS-AOU San 
Martino-IST, Genova, Italy, prior to surgery. Cartilage specimens were derived from 
relatively normal and from frankly osteoarthritic areas of the articular cartilage of the 
femoral condyles of each donor. Part of tissue samples were processed for grading (ICRS 
scale) and immunocytochemistry, as subsequently detailed. The remaining cartilage 
specimens of each area were cleared of connective tissue and/or subchondral bone, minced 
in small fragments and rinsed in fresh phosphate-buffered saline (PBS, pH 7.2). Cartilage 
fragments were enzymatically digested as previously reported (Narcisi et al., 2012). The 
isolated primary HAC were henceforward cultured in complete medium (Coon’s modified 
Ham’s F12 medium (Biochrom A.G., Berlin, Germany) with 10% fetal calf serum (FCS), 1% L-
glutamine) which was changed 3 days after plating and then twice a week. The culture 
dishes used for cell plating were pre-coated for 24 hours with culture medium to ease cell 
adhesion to the plastic. HAC from each donor were expanded in vitro until passage 1, 
detached by trypsinization, collected, counted and replated either for growth assessment, 
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immunofluorescence or gene expression assays in the presence/absence of different 
concentrations of Reversine (diluted in dimethyl sulfoxide, DMSO; final concentrations of 
500 nM, 1 μM or 5 μM). Control HAC were exposed to solvent DMSO alone. Aliquots of 
primary HAC of each donor/area were also used to generate high cell-density micromass 
cultures and maintained in chondrogenic medium for the following two weeks (Johnstone et 
al., 1998). 
 
2.2 Proliferation assays 
For growth kinetic experiments, 3X104 HAC were seeded in 24-well plates and maintained in 
F12 medium for additional 24 h. Non-attached cells were removed and cell growth 
evaluated by the Alamar BlueTM assay (Invitrogen, Milano, Italy) as indicated by the 
manufacturer. Briefly, at fixed time-points (0, 1, 2, 3 and 6 days after plating) cells, in all 
culturing conditions, were exposed to a complete medium containing 10% of the vital dye 
for 4 hours. Collected supernatants were spectrophotometrically evaluated at 600 and 570 
nm: absorbance variations correlate with the number of cells. Each time point, for each 
primary culture and condition, was assessed in triplicate/quadruplicate. Cell doublings were 
calculated with respect to the number of initially plated cells.  
 
2.3 Image analysis 
Images of cells in all different experimental culture conditions were acquired using a Nikon 
Digital Sight DS-5Mc camera, mounted on an OlympusBX5 1 fluorescence microscope, using 
Nikon imaging software NIS-Elements F, release 2.20. Image analysis was performed using 
the National Institute of Health Image J freeware (release 1.38X; http://rsb.info.nih.gov/iJ/). 
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Criteria used to include cells in the morphological evaluation were: (a) identification of 
single cells and of all their boundaries; (b) contemporaneous identification of the nuclear 
boundaries within the same cells; (c) identification of a major and a minor axis within the 
cell shape (Cy and Cx, respectively); (d) identification of a major and a minor axis within the 
nucleus shape (Ny and Nx, respectively). Axes were then measured by the program functions 
and the morphological ratio (Cy/Cx)/(Ny/Nx) calculated. A minimum of 100 
cells/treatment/primary culture were assessed to quantify the changes of the cell shape as a 
function of the culturing conditions. 
 
2.4 Immunohistochemistry and Immunofluorescence assays 
Cartilage specimens were washed in PBS, pH 7.2, fixed overnight in 4% paraformaldehyde, 
rinsed in PBS and embedded in paraffin. Sections (5 μm thickness) of normal (N) or 
osteoarthritic areas (OA) were cut, de-waxed and stained with Toluidine Blue, Alcian Blue an 
Safranin-O to evidence section morphology, according to standard protocols(Narcisi et al., 
2012), also applied for cytochemical analysis of cell pellets resulting from micromass 
cultures. Tissue and pellet sections were also challenged with anti type II collagen antibody 
(Developmental Studies Hybrydoma Bank, University of Iowa, Iowa City, Iowa, USA, cat.n. 
CIIC1), and revealed with standard procedures using a biotinylated goat-anti mouse 
secondary antibody (DakoCytomation, Dako Denmark A/S; DK-26000 Glostrup, Denmark; 
cat.n. E0433). Cultured HAC were instead fixed in 4% paraformaldehyde, rinsed in PBS and 
permeabilized with Hepes 20 mM, pH 7.4, Sucrose 300 mM, NaCl 50 mM, MgCl2 3 mM, 
Triton X-100 0.5% for 5 min at RT. Permeabilized HAC were than challenged with anti-β 
actin, anti-β tubulin or anti-active Caspase III (Sigma Aldrich, St. Louis, MO, USA, cat.n. A-
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2228, T-8660, and C-8487, respectively) antibodies, subsequently revealed with FITC- 
(Jackson ImmunoReasearch Lab. Europe Ltd., Suffolk, UK cat.n. 115-095-146) or PE-
conjugated (Jackson ImmunoReasearch Lab. Inc., cat.n. 111-116-144; or DakoCytomation, 
Dako Denmark A/S; DK-26000 Glostrup, Denmark; cat.n. R0439) secondary antibodies. 
 
2.5 High resolution DNA flow cytometric analysis (hr DNA-FCM) 
The DNA content in cell nuclei was determined as reported by Otto (Otto, 1994). Briefly, 
nuclei suspensions were obtained by incubating cells in lysis buffer containing Tween 20. 
Nuclei were filtered (50 µm nylon mesh), stained with DAPI and analyzed using a CyFlowML 
multiparameter flow cytometer (Sysmex Partek, Norderstedt, Germany). An UV mercury 
lamp (HBO-100 long life, 100W) was used to excite DAPI and the emitted light was collected 
by using the Gratz setting (488 blue solid laser shutdown; 435 nm long pass filter). 
 
2.6 Western blots 
Total proteins were extracted using the M-PER® Protein extraction reagent (Thermo 
Scientific, Pierce Biotechnology, Rockford, IL, USA) and quantitated by the Pierce BCA assay 
kit (Thermo Scientific). Equal amounts of total protein lysates per sample were subjected to 
4%-12% SDS-PAGE separation and transferred on PVDF membranes by standard Western 
blotting. Membranes were blocked for 2h in TBS-T buffer (20 mM Tris/HCl; 0.5 M NaCl; 0.1% 
Tween20) containing 5% dry milk powder, washed three times in TBS-T and incubated 
overnight at 4°C with anti-SOX9, anti-SMAD 2/3, anti phospho-SMAD 2/3 (Santa Cruz 
Biotechnology Inc. Europe, Heidelberg, Germany, cat.n.SC-20095,  SC-6032 and SC-11769, 
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respectively) or anti--actin (Sigma–Aldrich) in 5% low fat milk in TBS-T buffer. 
Immunodetection was performed adding HPR-linked secondary antibodies for 2h at room 
temperature, followed by visualization with ECLTM Prime Western Blottting Detection 
Reagent, on Amersham HyperfilmTM ECL chemiluminescence film (all from Amersham-GE 
Healthcare Ltd.; Little Chalfont, UK). 
 
 
2.7 Gene expression analysis 
Total messenger RNA was extracted according to the instructions of the PerfectPure RNA 
Cultured Cell Kit (5-Prime GmbH, Hamburg, Germany); cDNA pools were generated by using 
the SuperScriptTM III First-strand synthesis system for RT-PCR Kit (Invitrogen). Primer sets for 
each gene were derived from published sequences (glyceraldehyde-3-phosphate 
dehydrogenase, GAPDH; Sox9; Aggrecan, AGG; type II Collagen; SMAD 3 and 7; Matrix 
Metalloproteinase 13, MMP-13; Vascular endothelial Growth Factor, VEGF; see(Narcisi et 
al., 2012)), or purposely designed (Cyclin D1; Ki67; Transforming Growth Factor β-1, 2 or 3, 
TGF β-1, 2 or 3); Interleukin 1-β, IL-1β; Interleukin 6, IL-6; see Table 1). Relative expression of 
each gene was assessed by sybr-green real time quantitative RT-PCR; cDNAs samples were 
amplified with the RealMasterMix SYBR ROX 2,5X (5’-Prime) in an Eppendorf Mastecycler 
Realplex2 apparatus, performing quadruplicate reactions for each sample as follows: 95°C 
for 3 minutes; 35 cycles at 94°C for 30 sec, 60°C for 30 sec, 72°C for 40 sec, and a final step 
at 72°C for 7 min. The specificity of reaction products was counterchecked by melting curve 
analysis. Gene expression in each sample was normalized to the endogenous control gene 
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GAPDH. Expression levels in DMSO control cells was set as reference for further 
normalization among different primary cultures.  
 
2.8 Statistical evaluation 
To compare the effects on cell morphology of the various Reversine treatments across the 
different donors, a mixed effect linear statistical model was used, accounting for the 
repeated measurements within subjects (paired measurements) and for the different 
number of repetitions in each treatment group. Elsewhere the Mann-Whitney test was 
used. Whenever indicated *: 0.05>p>0.01; **: 0.01>p>0.001 and ***: p<0.001. 
 
3. RESULTS 
3.1 Reversine effects on cell growth and morphology. 
All OA cartilage samples presented evidences of indentations, fissures, fibrillation and cell 
proliferation (Figure 1A). A reduced differentiation potential of OA-HAC was confirmed by 
the cells inability to generate matrix-rich micromass cultures: sections resulted negative to 
immunostaining against type II collagen (Figure 1B); at the same time their proteoglycan 
content did not evidence cytopositive reaction to Toluidine Blue or Alcian blue, as well as it 
did not allow detection of mature lacunae in the cultured pellets, with respect to the 
relatively normal (N) HAC counterparts (Figure 1B). OA-HAC were then expanded in the 
presence of different concentrations of Rev to assess its effects on cell growth and 
morphology. Growth kinetics were significantly impaired in Rev-treated cells within 6 days 
of exposure at the highest concentrations (1.0-5.0 µM), whereas the lowest dose (500 nM) 
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did not elicit any variation with respect to DMSO alone-treated controls (Figure 1C). Aliquots 
of cells, previously exposed to 5.0 µM Rev for 6 days were shifted to the lowest Rev 
concentration (500 nM) for 6 additional days. Cell growth was resumed upon shifting, 
indicating that a constitutively high concentration of the drug was required to exert the 
observed effect on proliferation (Figure 1D). By converse Rev did not impair the proliferative 
activity of HAC derived from relatively normal areas of the same biopsies at any of the 
tested concentration (Figure 1E).  Morphologically, an evident loss of the fibroblast-like 
appearance of the cultured cells was detectable in all experimental conditions in which Rev 
was used, independently of its concentration (Figure 2A and 2B). Prolonging the exposure 
time to 500 nM Rev for additional 6 days did not elicit further variations; within the same 
time-frame, and in spite of a restored proliferative activity, OA-HAC shifted from 5.0 µM to 
500 nM Rev did not regain a fibroblast-like morphology (Figure 2A). Indeed, after 6 days, 
immunostaining procedures for β-tubulin and β-actin clearly called for a massive 
rearrangement of the cytoskeletal structures of the Rev-treated cells (Figure 2C). 
We then wondered if the morphological changes were contemporary to the effects exerted 
on cell proliferation. Hence, a time-dependent analysis of the appearance of the variations 
of the morphological determinants was performed, assessing the cell axes/nuclear axes 
ratio values at different timings upon Rev exposure. Shape changes appeared evident from 
the 4th day of treatment, peaking at days 5-6, concomitantly to the growth arrest effects 
(Figure 2D): within this timeframe in 5 µM- Rev-treated OA-HAC, 69% of the cells had gained 
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3.2 Reversine treatment affects cell proliferation by impairing cell cycle checkpoints. 
The interference raised by Rev with the mitotic spindle organization is described to block 
cells mainly in the G2/M (Chen et al., 2007) and G1/S transitions (Piccoli et al., 2012). We 
confirmed this assumption also for osteoarthritic chondrocytes by quantitative RT-PCR 
experiments, assessing the Ki67 and cyclin D1 mRNA levels. Our results evidenced a drastic 
reduction (>50%) of the transcript levels for Ki67, a well-known proliferation marker, in 1.0 
or 5.0 µM Rev-treated OA-HAC. This effect accounted for the reduced proliferation and was 
accordingly undetectable in 500nM-treated cells (Figure 3A, left panel). The cell attempt to 
overcome the block of the G1/S transition was testified by a notably enhanced RNA 
messenger level for cyclin D1, which averaged a 10-fold increase for 1.0 and 5.0 µM Rev-
treated OA-HAC (Figure 3A, right panel).  We also performed an analysis of the cell cycle 
phase distribution based on DNA content assessed by hr DNA-FCM in control and Rev-
treated OA-HAC; results evidenced a remarkable increment in Rev-treated cells of the G2/M 
phase percentage (from 6.7% to 14.6%), confirming the propensity of Rev to induce mitotic 
arrest and polyploidy. We therefore checked Rev-treated cultures for evidences of endo-
proliferation by nuclear counterstaining with DAPI; indeed, multiple nuclei could be 
detected within the same cells in all treated primaries (Figure 3B and 3C). Concomitantly to 
phenotypic changes, nuclear blebbing and active caspase-3-immunopositive cells were 
identified, suggesting that apoptotic onset was also induced upon Rev treatment (Figure 
3D). The cultured fibroblast-like OA-HAC, once exposed to Rev, had therefore gained a new 
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3.3 Reversine-induced morphological changes coexist with a modified gene expression 
pattern in OA-HAC 
We evaluated if the loss of fibroblast-like morphology in Rev-treated OA-HAC was also 
accompanied by a recovered expression of some relevant chondrogenic markers by means 
of real time RT-PCR analysis; we first focused onto the SOX9 transcription factor RNA 
messenger level, which peaked when OA-HAC were treated with the highest concentration 
of Rev, more than doubling the transcript level found in control cells (Figure 4A). Western 
blot and densitometric analysis confirmed the data for SOX9 also at the protein level, upon 
6 days of exposure to Rev (Figure 4B and 4C). Enhanced mRNA transcript levels were 
additionally found for Aggrecan, displaying a 5- to 7-fold increase in treated cells with 
respect to untreated control OA-HAC (Figure 4D). In accordance to a reduced proliferative 
activity, Rev-exposed cultured chondrocytes did not overexpressed the type I collagen 
mRNA (data not shown), but they also did not show any significant up-regulation of the type 
II collagen transcript (Figure 4E), a specific marker of articular chondrocytes. On the 
contrary, the more responsive N-HAC not only averaged a 7.41±0.50 fold-increase in Sox9 
expression in 5 µM Rev-treated cells, but also showed a contemporaneous 5.17±0.70 fold-
increase in type II collagen expression (Figure 4F and 4G). We then assessed the mRNA 
levels of some members of the TGF gene family, which revealed up-regulation of TGF β-1 
and β-2 transcripts upon 6 days of Rev exposure with respect to controls, reaching an 8- and 
a 5-fold respectively (Figure 5). In Rev-treated N-HAC, instead, the expression levels of the 
TGF family members remained substantially unaltered (data not shown). Hence we 
evaluated the phosphorylation status of SMAD2/3 in a western blotting setting, since 
receptor regulated SMAD 2 and 3 are canonically activated by TGF-β extracellular signals. 
SMAD 3 mRNA levels are increased after Rev treatment at the highest concentrations, but 
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no sign of increased phosphorylation could be detected by western blot approaches (Figure 
6A, 6B and 6C). On the contrary, the mRNA levels of the inhibitory SMAD7 resulted 
enhanced as a consequence of Rev exposure, reaching a 3-fold increase with respect to 
control DMSO only-treated OA-HAC (Figure 6D). A consequence of an altered fate of Rev-
exposed OA-HAC is also suggested by a marked overexpression of VEGF and MMP13 mRNAs 
(Figure 6D).   
A large body of evidence has previously supported the concept that chondrocyte 
hypertrophy may be started by inflammatory cytokines but that persistence of altered levels 
of pro-inflammatory molecules is, instead, detrimental to the osteogenic differentiation of 
bone marrow stromal cells (Kong et al., 2013). Indeed OA-HAC display higher levels of IL-1β 
and IL-6 mRNA than their normal counterparts (data not shown). Interestingly, Rev 
treatment lowers these levels in a dose-dependent fashion (Figure 6E); this effect is 
predominant on the IL-1β transcript, both amplitude- and time-wise, since it reduces the 
cytokine mRNA in OA-HAC treated with 5.0 µM Rev, within 3 and 6 days of treatment, to 1/5 
and then to 1/15 of the level in DMSO-alone treated OA-HAC, respectively. The down-




In this study we investigated the effects of Reversine on OA-HAC proliferation and 
differentiation to assess the potential of this purine inhibitor to elicit the cells chondrogenic 
commitment, and possibly to help bypass the current limitation of cell-based therapies in 
cartilage repair relative to OA-affected tissues. We observed that reversine induced 
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apoptosis in OA-HAC primary cultures and inhibited their proliferation in a dose-dependent 
manner, while it did not modify the growth of chondrocytes derived from relatively normal 
areas of the same biopsies. This inhibition required 3-6 days to appear and was dependent 
on the continuous presence of the chemical in the medium. A slow duplication rate of OA-
HAC (Giannoni et al., 2005) may account for the observed time-lag needed to disclose the 
Rev-driven proliferation delay in the heterogeneous primary cultures used.  The observed 
proliferation recovery may instead depend upon a fast regain of the cycling onset in those 
cells that have not changed their morphology (about 30% of the cells, even after a full week 
of exposure to 5 µM Rev). In particular, the Rev-treated OA-HAC underwent a G2/M arrest 
and a displayed a reduction of Ki67 expression; both effects are in agreement with the 
reported perturbation of the chromosome-microtubule attachment caused by Rev 
(Musacchio and Salmon, 2007) through inhibition of both Aurora B kinase and MPS1, a 
protein operating downstream of Aurora B required to recruit error correction checkpoint 
proteins onto unattached kinetochores (Santaguida et al., 2010). The observed increased 
expression of cyclin D in Rev-treated OA-HAC, instead, may be explained by the slippage of 
some cells from aberrant mitosis and re-entrance in the G1 phase; this interpretation is in 
accordance with the endoproliferation and polyploidy evidence also found in our study. 
Possibly a better general health condition of a “normal” chondrocyte (i.e. N-HAC, a non-
frank OA chondrocyte) enables the cell to react easily to exogenous stimuli and 
environmental variations: the undertaking of normal physiological responses, such as 
proliferation and metabolic activities, if with a sufficient momentum, would then result in 
protection from Rev effects. On the contrary, an OA-chondrocyte could represent an already 
sensitive target cell, prone to additional impairment. However not all the outcomes of Rev 
treatment are necessarily detrimental to the cell pro-chondrogenic properties. Indeed, we 
 
 
This article is protected by copyright. All rights reserved. 
have provided data that Rev modulates OA-HAC gene expression; the transcript levels of 
SOX9, Aggrecan, TGF β1-3 were up-regulated while those of IL 1-β and IL-6 were decreased. 
This pattern could suggest that Rev stimulated the chondrogenic potential of OA-HAC, 
considering that SOX9, Aggrecan and TGFs are expressed by metabolic active chondrocytes, 
while IL 1-β and IL-6 induce chondrocyte de-differentiation (Duan et al., 2015). However, the 
Rev-treated OA-HAC gene expression pattern appears rather aberrant, given i) the 
contemporary absence of enhancement of type II collagen expression in OA-HAC, which we, 
instead, observed in Rev-treated N-HAC; and ii) the increased expression of MMP13 and 
VEGF, which are upregulated in late hypertrophic chondrocytes involved in calcification of 
the cartilage ECM, or during the in vitro recapitulation of endochondral ossification induced 
by TGF-mediated signaling (Narcisi et al., 2012). However it should be also mentioned that 
IL-1β promotes prostaglandin E synthesis, which instead sustains cell differentiation and 
type II collagen expression (Tsuchida et al., 2014). Therefore a significant reduction in IL-1 β 
transcript may exert opposite outcomes, and further evaluation of the cytokine downstream 
effectors will be needed to elucidate this finding. Concerning the observed modulation of 
SMAD3 and SMAD7 by Rev in OA-HAC, it should be noticed that the SMAD3 transcript level 
was barely altered and was not paralleled by an increased protein amount, nor by an 
enhanced content of the activated (i.e.phosphorylated) protein. In this respect, though, it is 
formally possible that timing could be a key issue to detect up-regulation(s) of a transient 
effect. On the other hand, the observed induction of the inhibitory SMAD7 mRNA may be a 
compensatory mechanism to counteract the enhanced transcription of genes, such as MMP-
13 and VEGF, normally active during the endochondral ossification pathway. We also 
observed that Rev induced a profound change of the OA-HAC morphology, switching cell 
shape from an elongated (fibroblast-like) appearance to a rounded/polygonal one. This 
 
 
This article is protected by copyright. All rights reserved. 
modification was fully consistent with the observed tubulin and actin subcellular distribution 
patterns. We therefore suggest that all these morphological and gene expression changes 
induced by Rev in OA-HAC might be tightly interdependent. In fact chondrocytes sensitivity 
to microenvironmental changes and to their own tensegrity may contribute to alterations in 
gene expression (Ingber, 2006), as testified by their progressive de-differentiation once in a 
2D environment (Goldring and Goldring, 2007). Ideally, in a proper microenvironment, 
cultured normal chondrocytes resume the original phenotype, although this ability depends 
upon the age and wealth status of the cells themselves (Giannoni et al., 2005). Given the 
morphological changes observed upon treatment with Rev, then, the di-substituted purine 
could be envisaged to maintain higher levels of residual plasticity potential in the cultured 
chondrocytes. Reversine-induced cell rounding and growth arrest could contribute to an 
exogenously imposed mimicry of the canonical quiescent state of the cell, which rules the 
low metabolic activity of articular chondrocytes in cartilage. This, in turn, may drive a higher 
transcriptional potential for a cartilage specific factor, such as SOX9, which can thus 
enhance the expression of additional extracellular matrix component, as Aggrecan, like it 
normally does in normal HAC cultures (Henry et al., 2012). Speculatively, the p300/CBP 
complex (p300/CREB-Binding Protein complex) could actively participate to these SOX9-
mediated mechanisms; indeed its acetyl-transferase activity (Ha et al., 2009), as well as its 
functions as a transcriptional co-activator (Goodman and Smolik, 2000), are of paramount 
relevance for chromatin condensation/decondensation dynamics during the G2/M 
transition. Possibly, reversine-induced mitotic catastrophe could unleash p300/CBP from 
chromatin condensation. This, in turn, could provide a larger availability of the co-
transcriptional complex for specific binding with other factors (Polesskaya et al., 2001) 
among which SOX9, as demonstrated for the SMAD3-driven p300-mediated transactivation 
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of SOX9 during chondrogenesis (Furumatsu et al., 2005;Tsuda et al., 2003). In addition, also 
the TGF-β overexpression, as we detected in Rev-treated samples, can positively regulate 
p300 (Ghosh et al., 2013). In Rev-treated cells, receptor clustering and interaction with 
membrane proteins could be hypothesized, as previously indicated (Rudini et al., 2008), to 
enhance the standard TGF-mediated signaling, indirectly contributing to the SMAD 3-
dependent non-canonical pathway (Bauge et al., 2011). In conclusion the effects elicited by 
Rev on survival and differentiation of OA-HAC, at the cell-cycle checkpoint and gene 
expression levels, may provide, at the most, a slightly enhanced pro-chondrogenic 
environment. In spite of this usefulness for experimental settings, the Reversine residual 
apoptotic/cytotoxic effects and the proposed results do not call for a true “rejuvenation 
property” of the molecule itself, nor for its current application in a clinical scenario. 
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Figure 1. 
A: Toluidine blue, Alcian blue and Safranin-O staining of sections from control (N) or 
osteoarthritic cartilage (OA) from human donors; depicted sections are representative of 
the specimens derived from N and OA areas of the tissue of each donor. Arrowheads 
indicate evidence of fibrillation; arrows: cell proliferation. White bars: 100 µm and 25 µm 
(for 10X and 40X enlargements, respectively). B: Representative anti- type II collagen and 
Alcian Blue staining of original tissue sections (tis) or radial sections of micromass cultures 
(pel) of N or OA HAC derived from the same donor. BI: representative images of 
immunopositivity to anti-type II collagen antibody of original tissue sections (tis) derived 
from N or OA areas of the same bioptic specimen; white bars: 10 µm. BII: representative low 
magnification images of sections of micromass cultures (pel) derived from N or OA cells of 
the same specimen, stained with alcian blue (upper) or anti-type II collagen antibody 
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(lower), respectively; white bars: 100 µm. BIII: representative sections of micromass cultures 
(pel) derived from N or OA cells of the same specimen stained with Alcian blue; empty 
arrowheads indicate lacunae in the process of maturation; white bars: 10 µm. BIV: 
representative sections of micromass cultures (pel) derived from N or OA cells of the same 
specimen challenged with anti-type II collagen antibody; black arrowheads indicate positive 
cells. C: Proliferation kinetics of control (DMSO alone) and Reversine-treated OA HAC; 
treated cells were exposed to 500 nM, 1.0 µM and 5.0 µM Reversine, in DMSO, respectively. 
Each data point represents the average of the determinations performed on three different 
primary cultures, in two separate sets of experiments; each time point, for each primary 
culture and condition, was assessed in quadruplicate. Error bars depict standard deviation 
values. D: Proliferation kinetics of 5.0 µM Rev-treated OA HAC after shifting to a lower 
concentration of the chemical (500 nM; arrow). The proliferation curve of 500 nM Rev-
treated cells is also depicted for comparison. Data points as in C. E: Proliferation kinetics of 
control (DMSO alone) and Reversine-treated chondrocytes derived from normal cartilage; 
legend and data points as in C. 
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Figure 2. 
A: Evaluation of morphological changes induced in cultured OA HAC by exposure to 
Reversine. Cell morphological parameters were assessed in a minimum of 100 
cells/treatment for each primary culture (n = 3). Histograms depict the average ratio 
(Cy/Cx)/(Ny/Nx), as defined under the Material and Methods section; error bars depict 
standard deviation values; treatments include control (DMSO) and Reversine exposure (500 
nM, 1.0 µM and 5.00 µM) for 6 days. Cell aliquots of each primary culture were also exposed 
to Rev 500 nM for 6 additional days (Rev 500 nM 144h) or exposed to Rev 5.0 µM for 6 days 
and then shifted to Rev 500 nM (5.0 µM-500nM) for 6 additional days. Statistical 
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significance (*) was proved for each treatment with respect to DMSO (vs all); n.s.: not 
significant. B: representative images of control (DMSO) or Reversine-treated cells (5.0 µM); 
boxed areas in images of the left column are enlarged and show the assessed morphological 
parameters; white bars: 50 µm (panels in left column), 10 µm (in Enlarged, Cy/Cx and Ny/Nx 
colums). C: β-actin (A) or β-tubulin (T) immunofluorescence staining of control (DMSO) or 
Reversine-treated cells (5.0 µM); white bars: 25 µm or 10 µm, for large or small panels, 
respectively. D: Kinetics of morphological changes in cultured control (DMSO; empty bars) 
or Reversine-treated (Reversine, 5.0 µM; solid bars); morphological parameters were 
assessed in a minimum of 100 cells/treatment for each primary culture (n = 3); error bars 
depict standard deviation values. 
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Figure 3. 
A: Relative transcript levels of Ki67 (left) and Cyclin D1 (right) in control (DMSO alone, white 
bars) and Reversine-treated OA HAC samples (500 nM, light grey bars; 1.0 µM, dark grey 
bars; and 5.0 µM, black bars, respectively). Results depict the average expression of 3 
different primary OA HAC cultures and are normalized to controls. Error bars represent 
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standard deviations. B: Polynucleated cells evidenced by nuclear DAPI staining in Rev-
treated (5.0 µM) HAC, challenged with anti-β actin and FITC-conjugated secondary antibody. 
Arrows point to multinuclear cells. C: DAPI nuclear staining in control (DMSO) or in 
Reversine-treated (5.0 µM) OA HAC; arrowheads point to multiple and apoptotic nuclei. D: 
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Figure 4. 
A: SOX9 relative transcript levels in DMSO or Rev-treated OA HAC after 3 and 6 days of 
exposure to Reversine as assessed by real time RT-PCR. Histograms refer to controls (DMSO 
alone, white bars) and Reversine-treated OA HAC samples (500 nM, light grey bars; 1.0 µM, 
dark grey bars; and 5.0 µM, black bars, respectively). Histograms depict the average 
expression of 3 different primary OA HAC cultures and are normalized to controls. Error bars 
depict standard deviations. B: Representative immunoblot against SOX9 and β–Actin (β-Act) 
in control (CN) and Rev-treated (+R; 5.0 µM at 6 days) OA HAC lysates. C: Densitometric 
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analysis of the ratio of SOX9/ β–Actin protein levels. Histograms represent the average of 
the determinations performed on lysates of two different OA HAC primaries; results are 
expressed as arbitrary densitometric units (A.U.) and normalized to controls; error bars 
depict standard deviations. D-E: Gene expression analysis of Aggrecan (D) or Type II Collagen 
(E) in control or Rev-treated OA HAC after 3 and 6 days of exposure. F-G: Gene expression 
analysis of SOX9 (F) or Type II Collagen (G) in control or Rev-treated N HAC after 3 and 6 
days of exposure. Results are the average of three different primary culture tested; error 
bars depict standard deviations.  
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Figure 5. 
Real time RT-PCR gene expression analysis of the relative transcript levels for TGF β-1, -2 
and -3 in control and Rev-treated OA HAC after 3 and 6 days of exposure to Reversine. 
Histograms refer to controls (DMSO alone, white bars) and Reversine-treated OA HAC 
samples (500 nM, light grey bars; 1.0 µM, dark grey bars; and 5.0 µM, black bars, 
respectively) and display the average values of three different primary cultures tested; data 
are normalized to controls; error bars depict standard deviations. 
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A: SMAD3 relative transcript levels in DMSO or Rev-treated OA HAC after 3 and 6 days of 
exposure to Reversine as assessed by real time RT-PCR. Results depict the average 
expression of 3 different primary OA HAC cultures and are normalized to controls. 
Histograms refer to controls (DMSO alone, white bars) and Reversine-treated OA HAC 
samples (500 nM, light grey bars; 1.0 µM, dark grey bars; and 5.0 µM, black bars, 
respectively). Error bars depict standard deviations. B: Representative immunoblot against 
phosphorylated SMAD3 (pSMAD3) and total SMAD3 in control (CN) and Rev-treated (+R; 5.0 
µM at 6 days) OA HAC lysates. C: Densitometric analysis of the ratio of pSMAD3/ β–Actin 
protein levels. Histograms represent the average of the determinations performed on 
lysates of two different OA HAC primaries; results are expressed as arbitrary densitometric 
units (A.U.) and normalized to controls; error bars depict standard deviations. D: Gene 
expression analysis of SMAD7, MMP-13 and VEGF in DMSO- or Rev-treated OA HAC after 6 
days of exposure to different concentrations of Reversine. E: Gene expression analysis of IL-
1β or IL-6 in control or Rev-treated OA HAC after 6 days of exposure. Histograms refer to 
controls (DMSO alone, white bars) and Reversine-treated OA HAC samples (500 nM, light 
grey bars; 1.0 µM, dark grey bars; and 5.0 µM, black bars, respectively). Results are the 






Custom-designed primer sequences 
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Target gene Forward primer   Reverse primer 
Cyclin D1 5’-CgTggCCTCTAAgATgAAgg  5’-AgCTTgTTcACCAggAgCAg 
Ki67   5’-CACTTTggAgAgCAAATCTgTg 5’-CACTgTCCCTATgACTTCTgg 
TGF β-1 5’-ACgTggAgCTgTACCAgAAAT 5’-CCggTAgTgAACCCgTTgAT 
TGF β-2 5’-gCTATATCAgATTCTCAAgTCC 5’-CCAggTTCCTgTCTTTATggT 
TGF β-3 5’-CACAACgAACTggCTgTCTg  5’-CAAgACCCggAATTCTgCTC 
IL 1-β  5’-gCAAgggCTTCAggCAggCCgC 5’-gTCATTCTCCTggAAggTCTgTgggC 
IL-6  5’-ggTACATCCTCgACggCATCT 5’-gCCTCTTTgCTgCTTTCAC 
 
 
